Treatment of community-acquired pneumonia typically involves either a respiratory fluoroquinolone or a combination of cephalosporin and a macrolide. Initial broad-spectrum antibiotic therapy should ...

Whether the antiinflammatory and immunomodulatory effects of glucocorticoids may decrease mortality among patients with severe community-acquired pneumonia is unclear. In this phase 3, multicenter, ...

More data stressing innovative "nontraditional" approaches to the antibiotic management of community-acquired pneumonia, such as home intravenous treatment and therapy with oral antibiotics, are ...

Community-acquired pneumonia (CAP) in children involves a notable inflammatory response. Although the inflammatory response is part of the host's effort to fight infection, it is unclear whether ...

The FDA has approved the supplemental New Drug Application for Baxdela for the treatment of community acquired bacterial pneumonia in adult patients.

Full results of the post-hoc analysis of LEAP 2 data is included in the paper titled: Oral 5-Day Lefamulin for Outpatient Management of Community-Acquired Bacterial Pneumonia: Post Hoc Analysis of ...

Background: We investigated whether the use of respiratory fluoroquinolones was associated with better clinical outcomes compared with the use of macrolides and β- lactams among adults with pneumonia.

Community-acquired pneumonia (CAP) is associated with increased risk of long-term adverse events.

Community-acquired pneumonia should not be regarded as a seasonal disease linked to winter, as it occurs throughout all four seasons, according to Spanish researchers. However, they acknowledged that ...

“This study provides additional data confirming NUZYRA as an effective and well-tolerated treatment option for community-acquired bacterial pneumonia, a serious respiratory illness with ...